Metalloproteinase inhibition protects against cardiomyocyte injury during experimental acute pulmonary thromboembolism

Critical Care Medicine

Volumn 39, Issue 2, 2011, Pages 349-356

  Neto Neves, Evandro M ^a   Dias Junior, Carlos A ^b   Rizzi, Elen ^a   Castro, Michele M ^a   Sonego, Fabiane ^a   Gerlach, Raquel F ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

acute pulmonary thromboembolism; doxycycline; matrix metalloproteinases; pulmonary embolism; pulmonary hypertension; troponin

Indexed keywords

DOXYCYCLINE; GELATINASE A; GELATINASE B; TROPONIN I;

ACUTE PULMONARY THROMBOEMBOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL DOG; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART RIGHT ATRIUM; HEART RIGHT VENTRICLE; HEMODYNAMICS; HYPERTENSION; LUNG EMBOLISM; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

EID: 79251538289     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181fa3dfe     Document Type: Article

References (34)

1. Wood KE: Major pulmonary embolism: Review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877-905
2. Dias-Junior CA, Montenegro MF, Florencio BC, et al: Sildenafil improves the beneficial haemodynamic effects of intravenous nitrite infusion during acute pulmonary embolism. Basic Clin Pharmacol Toxicol 2008; 103: 374-379
3. Dias-Junior CA, Souza-Costa DC, Zerbini T, et al: The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth Analg 2005; 101:115-120, table of contents (Pubitemid 40853360)
4. Dias-Junior CA, Vieira TF, Moreno H Jr, et al: Sildenafil selectively inhibits acute pulmonary embolism-induced pulmonary hypertension. Pulm Pharmacol Ther 2005; 18: 181-186
5. Palei ACT, Zaneti RAG, Fortuna GM, et al: Hemodynamic benefits of matrix metalloproteinase- 9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology 2005; 5:611-617
6. Fortuna GM, Figueiredo-Lopes L, Dias- Junior CA, et al: A role for matrix metalloproteinase- 9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 2007; 114:22-27
7. Souza-Costa DC, Figueiredo-Lopes L, Alves-Filho JC, et al: Protective effects of atorvastatin in rat models of acute pulmonary embolism: Involvement of matrix metalloproteinase-9. Crit Care Med 2007; 35:239-245
8. Souza-Costa DC, Zerbini T, Palei AC, et al: L-arginine attenuates acute pulmonary embolism- induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase. Chest 2005; 128:3705-3710.
9. Van den Steen PE, Dubois B, Nelissen I, et al: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37:375-536
10. Chow AK, Cena J, Schulz R: Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152:189-205
11. Schulz R: Intracellular targets of matrix metalloproteinase- 2 in cardiac disease: Rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47:211-242
12. Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833-1839
13. Kandasamy AD, Chow AK, Ali MA, et al: Matrix metalloproteinase-2 and myocardial oxidative stress injury: Beyond the matrix. Cardiovasc Res 2010; 85:413-423
14. Lalu MM, Pasini E, Schulze CJ, et al: Ischaemia- reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 2005; 26:27-35
15. Sawicki G, Leon H, Sawicka J, et al: Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: A new intracellular target for matrix metalloproteinase-2. Circulation 2005; 112: 544-552
16. Wang W, Schulze CJ, Suarez-Pinzon WL, et al: Intracellular action of matrix metalloproteinase- 2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106:1543-1549
17. Horlander KT, Leeper KV: Troponin levels as a guide to treatment of pulmonary embolism. Curr Opin Pulm Med 2003; 9:374-377
18. Uzuelli JA, Dias-Junior CA, Tanus-Santos JE: Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta 2008; 388:184-188
19. Cau SB, Dias-Junior CA, Montenegro MF, et al: Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur J Pharmacol 2008; 581:132-137
20. Dias-Junior CA, Gladwin MT, Tanus-Santos JE: Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med 2006; 41:1764-1770
21. Jacob-Ferreira AL, Palei AC, Cau SB, et al: Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine. Eur J Pharmacol 2010; 627:216-222
22. Dias-Junior CA, Cau SB, Oliveira AM, et al: Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase- 9 and oxidative stress. Thromb Res 2009; 124:349-355
23. Castro MM, Rizzi E, Figueiredo-Lopes L, et al: Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331
24. Ceron CS, Castro MM, Rizzi E, et al: Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010; 160:77-87
25. Castro MM, Rizzi E, Rodrigues GJ, et al: Antioxidant treatment reduces matrix metalloproteinase- 2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009; 46:1298-1307
26. Souza DG, Cassali GD, Poole S, et al: Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury. Br J Pharmacol 2001; 134:985-994
27. Watts JA, Zagorski J, Gellar MA, et al: Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 2006; 41:296-307
28. Watts JA, Gellar MA, Obraztsova M, et al: Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol 2008; 89:389-399
29. Zagorski J, Gellar MA, Obraztsova M, et al: Inhibition of CINC-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J Immunol 2007; 179: 7820-7826
30. Watts JA, Gellar MA, Stuart LK, et al: Proin-flammatory events in right ventricular damage during pulmonary embolism: Effects of treatment with ketorolac in rats. J Cardiovasc Pharmacol 2009; 54:246-252
31. Kucher N, Goldhaber SZ: Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108: 2191-2194 (Pubitemid 37363033)
32. Müller-Bardorff M, Weidtmann B, Giannitsis E, et al: Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002; 48: 673-675.
33. Fridman R, Toth M, Peñ a D, et al: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55:2548-2555
34. Parikh SV, de Lemos JA: Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 2006; 332:186-197